课题基金 / 基金详情

PRAMLINTIDE VS PLACEBO IN PATIENTS WITH TYPE 1 DIABETES MELLITUS

PRAMLINTIDE VS PLACEBO IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
普兰林肽与安慰剂在 1 型糖尿病患者中的治疗效果
批准号：
6244778
负责人：
ADINA ZEIDLER
金额：
$3.96万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-23 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244778
关键词：
blood glucose clinical research clinical trials diabetes mellitus therapy dosage drug screening /evaluation glucose metabolism hemoglobin hormone therapy human subject human therapy evaluation hyperglycemia injection /infusion insulin dependent diabetes mellitus pancreatic polypeptide peptide hormone placebos

项目摘要

项目成果

ADINA ZEIDLER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study is: 1) to determine the effects of Pramlintide(Amylin) on glucose control in Type I diabetes through the assessment of hemoglobin A1C, and 2) to determine the safety of two doses of Pramlintide compared to placebo when administered by subcutaneous injection to Type I diabetes mellitus. The hypothesis to be tested is if Pramlintide improves the control of Type I diabetes, particularly reducing blood glucose in the postprandial hyperglycemic state.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DIABETES PREVENTION TRIAL--TYPE I DIABETES
GENETICS OF IDDM IN MEXICAN AMERICAN FAMILIES
FEASIBILITY OF ORAL INSULIN THERAPY TO DELAY BETA CELL DESTRUCTION
DIABETES PREVENTION TRIAL--TYPE I DIABETES
海外基金